Volume 10, Issue 4 (2024)
IEM 2024, 10(4): 297-308 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Dehghani T, Najafi Deloui M, Aryan E, Meshkat Z, Hooshyar Chechaklou A, Tavalaie S, et al . Associations of Cardiovascular Diseases with Hepatitis B and D , and Metabolic Syndrome in Mashhad, Iran: A Cross-Sectional Study. IEM 2024; 10 (4) :297-308
URL: http://iem.modares.ac.ir/article-4-70955-en.html
URL: http://iem.modares.ac.ir/article-4-70955-en.html
Toktam Dehghani1 
, Mojtaba Najafi Deloui2 , Ehsan Aryan1 , Zahra Meshkat3 , Amin Hooshyar Chechaklou3 , Shima Tavalaie4 , Naeim Haghighatdoost2 , Mojtaba Meshkat5 , Mahdieh Khoshakhlagh6 , Samaneh Abolbashari3 , Aida Gholoobi * 7
, Mojtaba Najafi Deloui2 , Ehsan Aryan1 , Zahra Meshkat3 , Amin Hooshyar Chechaklou3 , Shima Tavalaie4 , Naeim Haghighatdoost2 , Mojtaba Meshkat5 , Mahdieh Khoshakhlagh6 , Samaneh Abolbashari3 , Aida Gholoobi * 7
1- Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2- Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
3- Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4- Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
5- Department of Community Medicine, Faculty of Medicine, Mashhad Medical Science, Islamic Azad University, Mashhad, Iran.
6- Metabolic Syndrome Research Center, Mashhad University of Medical Science, Mashhad, Iran. Department of Community Medicine, Faculty of Medicine, Mashhad Medical Science, Islamic Azad University, Mashhad, Iran.
7- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ,gholoubiad@mums.ac.ir
2- Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
3- Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4- Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
5- Department of Community Medicine, Faculty of Medicine, Mashhad Medical Science, Islamic Azad University, Mashhad, Iran.
6- Metabolic Syndrome Research Center, Mashhad University of Medical Science, Mashhad, Iran. Department of Community Medicine, Faculty of Medicine, Mashhad Medical Science, Islamic Azad University, Mashhad, Iran.
7- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ,
Abstract: (507 Views)
Background: Viral infections may play a significant role in the development of heart failure, especially in people with related cardiac conditions such as myocarditis. Hepatitis B and D viruses (HBV-HDV) are potentially fatal liver infections. This study examined the influence of metabolic syndrome and its associated disorders.
Materials & Methods: This cross-sectional study investigated hepatitis D antibody and hepatitis B surface antigen (HBsAg) in 239 people aged 35 to 65 years in Mashhad, Khorasan Razavi Province, Iran in 2018-2019. There were two study groups: those with cardiovascular diseases (CVD) and healthy individuals. Serum samples of all subjects in both groups were examined using enzyme-linked immunosorbent assay (ELISA).
Findings: HDV infection was detected in none of the study groups. Only one patient (0.8%) in the case group tested positive for HBsAg. The average LDL (low-density lipoprotein) (p= .8) and cholesterol (p= .3) levels in terms of lipid profiles were similar in both groups. Although the mean high-density lipoprotein (HDL) level in the patient group was lower, the mean triglyceride level in this group was higher than in the control group. Fasting blood sugar (FBS) (p= .009) and aspartate aminotransferase (AST) levels were significantly higher in CVD patients, while 59.3% of them exhibited metabolic syndrome.
Conclusion: This study results demonstrate no connection between HBV/HDV infection and cardiovascular diseases. The findings confirm that metabolic syndrome and hyperglycemia are underlying factors in cardiovascular diseases. Changes in HDL and triglyceride levels could impact cardiovascular diseases more than other lipids.
Materials & Methods: This cross-sectional study investigated hepatitis D antibody and hepatitis B surface antigen (HBsAg) in 239 people aged 35 to 65 years in Mashhad, Khorasan Razavi Province, Iran in 2018-2019. There were two study groups: those with cardiovascular diseases (CVD) and healthy individuals. Serum samples of all subjects in both groups were examined using enzyme-linked immunosorbent assay (ELISA).
Findings: HDV infection was detected in none of the study groups. Only one patient (0.8%) in the case group tested positive for HBsAg. The average LDL (low-density lipoprotein) (p= .8) and cholesterol (p= .3) levels in terms of lipid profiles were similar in both groups. Although the mean high-density lipoprotein (HDL) level in the patient group was lower, the mean triglyceride level in this group was higher than in the control group. Fasting blood sugar (FBS) (p= .009) and aspartate aminotransferase (AST) levels were significantly higher in CVD patients, while 59.3% of them exhibited metabolic syndrome.
Conclusion: This study results demonstrate no connection between HBV/HDV infection and cardiovascular diseases. The findings confirm that metabolic syndrome and hyperglycemia are underlying factors in cardiovascular diseases. Changes in HDL and triglyceride levels could impact cardiovascular diseases more than other lipids.
Keywords: Cardiovascular diseases, Hepatitis B, Hepatitis D, Hepatitis B surface antigens, Metabolic syndromes
Article Type: Original Research |
Subject:
Virology
Received: 2023/08/7 | Accepted: 2024/11/24 | Published: 2024/12/20
Received: 2023/08/7 | Accepted: 2024/11/24 | Published: 2024/12/20
References
1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. [DOI:10.1016/j.jacc.2020.11.010] [PMID] []
2. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol. 2019;74(20):2529-32. [DOI:10.1016/j.jacc.2019.10.009] [PMID]
3. Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332-45
4. Saki N, Karandish M, Cheraghian B, Heybar H, Hashemi SJ, Azhdari M. Prevalence of cardiovascular diseases and associated factors among adults from southwest Iran: Baseline data from Hoveyzeh cohort study. BMC Cardiovasc Disord. 2022;22(1);1-10. [DOI:10.1186/s12872-022-02746-y] [PMID] []
5. Cowan LT, Buck B, Schwind JS, Lutsey PL, Pankow JS, Matsushita K, et al. Triggering of cardiovascular disease by infection type: The atherosclerosis risk in communities study (ARIC). Int J Cardiol. 2021;325:155-60. [DOI:10.1016/j.ijcard.2020.09.073] [PMID] []
6. Fahed G, Aoun L, Zerdan MB, Allam S, Zerdan MB, Bouferraa Y, et al. Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23(2):786. [DOI:10.3390/ijms23020786] [PMID] []
7. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal - Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289-304. [DOI:10.2337/diacare.28.9.2289] [PMID]
8. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: The casale Monferrato study. Diabetes Care. 2004;27(11):2689-94. [DOI:10.2337/diacare.27.11.2689] [PMID]
9. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: The strong heart study. Diabetes Care. 2003;26(3):861-7. [DOI:10.2337/diacare.26.3.861] [PMID]
10. Simanek AM, Dowd JB, Aiello AE. Persistent pathogens linking socioeconomic position and cardiovascular disease in the US. Int J Epidemiol. 2009;38(3):775-87. [DOI:10.1093/ije/dyn273] [PMID] []
11. Sorriento D, Iaccarino G. Inflammation and cardiovascular diseases: The most recent findings. Int J Mol Sci. 2019;20(16):3879. [DOI:10.3390/ijms20163879] [PMID] []
12. Khademi F, Vaez H, Momtazi-Borojeni AA, Majnooni A, Banach M, Sahebkar A. Bacterial infections are associated with cardiovascular disease in Iran: A meta-analysis. Arch Med Sci. 2019;15(4):902-11. [DOI:10.5114/aoms.2019.85509] [PMID] []
13. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-65. [DOI:10.1086/518849] [PMID]
14. Monsey L, Best LG, Zhu J, DeCroo S, Anderson MZ. The association of mannose binding lectin genotype and immune response to Chlamydia pneumoniae: The strong heart study. PLoS One. 2019;14(1):e0210640. [DOI:10.1371/journal.pone.0210640] [PMID] []
15. Xue L, Liang YH, Gao YY, Wang XJ. Clinical study of Chlamydia pneumoniae infection in patients with coronary heart disease. BMC Cardiovasc Disord. 2019;19(1):1-6. [DOI:10.1186/s12872-019-1099-y] [PMID] []
16. Yombi JC, Yuma SN, Pasquet A, Astarci P, Robert A, Rodriguez HV. Staphylococcal versus streptococcal infective endocarditis in a tertiary hospital in Belgium: Epidemiology, clinical characteristics, and outcome. Acta Clin Belg. 2017;72(6):417-23. [DOI:10.1080/17843286.2017.1309341] [PMID]
17. Hanson PJ, Liu-Fei F, Minato TA, Hossain AR, Rai H, Chen VA, et al. Advanced detection strategies for cardiotropic virus infection in a cohort study of heart failure patients. Lab Investig. 2022;102(1):14-24. [DOI:10.1038/s41374-021-00669-4] [PMID] []
18. Kong KA, Jung S, Yu M, Park J, Kang IS. Association between cardiovascular risk factors and the severity of coronavirus disease 2019: Nationwide epidemiological study in Korea. Front Cardiovasc Med. 2021;8:732518. [DOI:10.3389/fcvm.2021.732518] [PMID] []
19. Duan J, Wu Y, Liu C, Yang C, Yang L. Deleterious effects of viral pneumonia on cardiovascular system. Eur Heart J. 2020;41(19):1833-8. [DOI:10.1093/eurheartj/ehaa325] [PMID]
20. Schultheiss HP, Baumeier C, Pietsch H, Bock CT, Poller W, Escher F. Cardiovascular consequences of viral infections: From COVID to other viral diseases. Cardiovasc Res. 2021;117(13):2610-23. [DOI:10.1093/cvr/cvab315] [PMID] []
21. Leone O, Pieroni M, Rapezzi C, Olivotto I. The spectrum of myocarditis: From pathology to the clinics. Virchows Arch. 2019;475(3):279-301. [DOI:10.1007/s00428-019-02615-8] [PMID]
22. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, Timmis AD, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: A CALIBER self-controlled case series study. J Infect Dis. 2012;206(11):1652-9. [DOI:10.1093/infdis/jis597] [PMID] []
23. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345-53. [DOI:10.1056/NEJMoa1702090] [PMID]
24. Gopal R, Marinelli MA, Alcorn JF. Immune mechanisms in cardiovascular diseases associated with viral infection. Front Immunol. 2020;11:570681. [DOI:10.3389/fimmu.2020.570681] [PMID] []
25. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-90. [DOI:10.1038/s41591-022-01689-3] [PMID] []
26. Feinstein MJ. HIV and cardiovascular disease: From insights to interventions. Top Antivir Med. 2021;29(4):407-11.
27. Pyarali F, Iordanov R, Ebner B, Grant J, Vincent L, Toirac A, et al. Cardiovascular disease and prevention among people living with HIV in south Florida. Medicine. 2021;100(28):e26631. [DOI:10.1097/MD.0000000000026631] [PMID] []
28. Nikitskaya E, Lebedeva A, Ivanova O, Maryukhnich E, Shpektor A, Grivel JC, et al. Cytomegalovirus-productive infection is associated with acute coronary syndrome. J Am Heart Assoc. 2016;5(8):e003759. [DOI:10.1161/JAHA.116.003759] [PMID] []
29. Jeong SJ, Ku NS, Han SH, Choi JY, Kim CO, Song YG, et al. Anti-cytomegalovirus antibody levels are associated with carotid atherosclerosis and inflammatory cytokine production in elderly Koreans. Clin Chim Acta. 2015;445:65-9. [DOI:10.1016/j.cca.2015.03.015] [PMID]
30. Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis, and cardiovascular disease: What impact of direct-acting antiviral treatments? World J Gastroenterol. 2018;24(41):4617-21. [DOI:10.3748/wjg.v24.i41.4617] [PMID] []
31. Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of cardiovascular disease due to chronic hepatitis C infection: A review. J Clin Transl Hepatol. 2017;5(4):343-62. [DOI:10.14218/JCTH.2017.00021] [PMID] []
32. Salehi-Vaziri M, Sadeghi F, Hashiani AA, Fesharaki MG, Alavian SM. Hepatitis B virus infection in the general population of Iran: An updated systematic review and meta-analysis. Hepat Mon. 2016;16(4):e35577. [DOI:10.5812/hepatmon.35577]
33. Shakeri MT, Foghanian B, Nomani H, Ghayour-Mobarhan M, Nabavinia MS, Rostami S, et al. The prevalence of hepatitis B virus infection in Mashhad, Iran: A population-based study. Iran Red Crescent Med J. 2013;15(3):245-8. [DOI:10.5812/ircmj.8200] [PMID] []
34. Huang PL. A comprehensive definition for metabolic syndrome. DMM Dis Model Mech. 2009;2(5-6):231-7. [DOI:10.1242/dmm.001180] [PMID] []
35. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am Coll Cardiol. 2004;43(10):1731-7. [DOI:10.1016/j.jacc.2003.12.047] [PMID]
36. Yano Y, Reis JP, Colangelo LA, Shimbo D, Viera AJ, Allen NB, et al. Association of blood pressure classification in young adults using the 2017 American College of Cardiology/American Heart Association blood pressure guideline with cardiovascular events later in life. J Am Med Assoc. 2018;320(17):1774-82. [DOI:10.1001/jama.2018.13551] [PMID] []
37. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Li CP. High blood pressure and all-cause and cardiovascular disease mortalities in community-dwelling older adults. Medicine. 2015;94(47):e2160. [DOI:10.1097/MD.0000000000002160] [PMID] []
38. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57-70. [DOI:10.1016/j.trsl.2017.01.001] [PMID] []
39. Zhao X, Wang D, Qin L. Lipid profile and prognosis in patients with coronary heart disease: A meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2021;21(1):1-15.
https://doi.org/10.1186/s12872-015-0179-x [DOI:10.1186/s12872-020-01835-0] [PMID] []
40. Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9(1):1-13. [DOI:10.1186/s13098-017-0225-1] [PMID] []
41. Sung J, Song YM, Choi YH, Ebrahim S, Smith GD. Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction. Stroke. 2007;38(5):1436-41. [DOI:10.1161/STROKEAHA.106.466268] [PMID]
42. Wang CH, Chen CJ, Lee MH, Yang HI, Hsiao CK. Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year follow-up study based on 22,472 residents in Taiwan. Atherosclerosis. 2010;211(2):624-9. [DOI:10.1016/j.atherosclerosis.2010.03.008] [PMID]
43. Wu VC, Chen TH, Wu M, Cheng CW, Chen SW, Chang CW, et al. Comparison of cardiovascular outcomes and all-cause mortality in patients with chronic hepatitis B and C: A 13-year nationwide population-based study in Asia. Atherosclerosis. 2018;269:178-84. [DOI:10.1016/j.atherosclerosis.2018.01.007] [PMID]
44. Chun HS, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, et al. Prevalence and risk factors of cardiovascular disease in patients with chronic hepatitis B. Dig Dis Sci. 2021;67(7):3412-25. [DOI:10.1007/s10620-021-07157-1] [PMID]
45. Demir M, Demir C. Effect of hepatitis B virus infection on right and left ventricular functions. Med Sci Monit. 2012;18(9):CR587. [DOI:10.12659/MSM.883356] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |